Navigation Links
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Date:5/6/2009

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting

SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently completed Phase 2 clinical development with potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

The presentations are as follows:

Saturday, May 16th

Oral Presentation - Lecture Hall 3a (14:54 - 15:06)

  • O28: In vivo pharmacodynamics of TR-701, a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde, R. Kulawy, G. Drusano

Sunday, May 17th

Poster Presentations - New antimicrobials against Gram-positives (13:30 - 14:30)

  • P 1091: Effects of food on the pharmacokinetics of TR-701, a novel oxazolidinone prodrug antibiotic, in healthy adult subjects; KA. Munoz, P. Bien, P. Prokocimer, M. Berry, C. R. Bethune
  • P 1092: TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates extensively within human macrophages cells and shows activity towards intraphagocytic linezolid-sensitive and linezolid-resistant
    '/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
2. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
5. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
6. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
8. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
11. Vantia Therapeutics Pipeline Continues to Mature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... BioSpecifics Technologies Corp. (Nasdaq: BSTC ... collagenase-based products, today announced top-line efficacy and safety ... XIAFLEX(TM) for the treatment of Peyronie,s disease. Peyronie,s ... collagen on the shaft of the penis, which ... difficult or impossible in advanced cases. The Phase ...
(Date:12/16/2009)... CVS/pharmacy and MinuteClinic health care centers located in ... in 20 states and Washington, D.C. While ... vaccines continue, many states have lifted restrictions, allowing ... shot while supplies last. In addition, seasonal ... at MinuteClinic locations across the country on demand ...
(Date:12/16/2009)... -- Vivakor, Inc. (OTC Bulletin Board: VIVK) ... Baker Consulting out of Walnut Creek, California ... out of South Florida. Baker Consulting ... with business development, financing and assisting the ... Specifically, Baker Consulting is exploring potential acquisition ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4Vivakor Signs Business Development Agreement With Baker Consulting 2Women More Prone to Die in Month After Heart Attack 55329 1Women More Prone to Die in Month After Heart Attack 55329 2Women More Prone to Die in Month After Heart Attack 55329 3More Women Surviving After Early Breast Cancer 55327 1More Women Surviving After Early Breast Cancer 55327 2More Women Surviving After Early Breast Cancer 55327 3Standard 26amp 3B Poor 26apos 3Bs Upgrades Wellmont Outlook 55325 1Standard 26amp 3B Poor 26apos 3Bs Upgrades Wellmont Outlook 55325 2Standard 26amp 3B Poor 26apos 3Bs Upgrades Wellmont Outlook 55325 3
... of pivotal trial confirms that more patients,are alive ... 2007-A follow-up analysis tracking,the outcome of patients with ... innovative cancer therapy MabThera,(rituximab) over seven years ago ... the original pivotal phase III study has shown,that ...
... Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences ... 2,monotherapy trial showing that tanespimycin demonstrated antitumor,activity ... one patient with a BRAF mutation (V600E) ... of initiation) and while on,tanespimycin demonstrated progression-free ...
Other Medicine Technology:MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 2MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 4Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 2Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 3Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 4
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a ... one of its portfolio companies, Acclarent, Inc., has ... by Ethicon, Inc., a Johnson & Johnson company, ... (net of estimated cash on hand at time ... designing, developing and commercializing devices that address conditions ...
(Date:12/16/2009)... -- Allscripts (Nasdaq: MDRX ) announced today ... the three and six months ended November 30, ... January 11, 2010. Allscripts management will host a ... earnings and other information at 8:30 AM Eastern ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter ...
(Date:12/16/2009)... possibly deadly, attack is long-term goal, researchers say ... developed a tool to predict whether a patient will ... first stroke. , "This is an important new tool ... second stroke soon after a first stroke are more ... Ay, of Massachusetts General Hospital and Harvard Medical School, ...
(Date:12/16/2009)... researchers at work on a malaria elimination study in ... of the disease using cell phone records. , The ... how often residents of Zanzibar travel and where they ... the coast of Tanzania in East Africa, Zanzibar has ... the study as part of deliberations on whether to ...
(Date:12/16/2009)... caution, though, that no direct link has been found, ... bacteria in food -- commonly linked to food poisoning ... might also be the cause of some urinary tract ... the bacteria in chicken from stores and restaurants and ... evidence that the germs were transmitted directly to the ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3
... Inc. (Nasdaq: ALXA ) announced today that ... Cowen & Company 29th Annual Healthcare Conference on Tuesday, ... The presentation will be webcast from the Boston Marriott ... the Web, please go to the Investor Relations tab ...
... finds it works on kids, teens having heart attacks ... widespread belief that cardiac resuscitation is not effective in ... that the rescue measure is worth the effort with ... arrest can be caused by heart disease, heart attack, ...
... Healthcare (CXHC) announces the recent addition of Michael ... Michael will be responsible for further development and ... Publication CONNEXION business units, as well as initiation ... )Michael comes to CXHC with more than 20 ...
... are often resistant to standard cancer therapies such as ... of available treatments for melanoma, the prognosis for patients ... the National Cancer Institute at the National Institutes of ... to restore the sensitivity of melanomas to RA, suggesting ...
... 9 /PRNewswire/ -- SecureWorks(R), one ... has contracted with Columbian-based ETEK International to extend its ... markets. One of South America,s leading security providers, ... services which include, among others, Intrusion Prevention and Detection, ...
... ProteoTech Inc. announced today that both Dr. ... Esposito, Director of In Vitro Screening, will present ... to be held in Prague, Czech Republic, March 11-15, 2009. ... give an oral presentation discussing promising results pertaining to ProteoTech,s ...
Other Medicine News:Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 2Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 3Health News:CPR Can Save Young Lives, Too 2Health News:Michael Forte Joins CONNEXION Healthcare as Chief Operations Officer 2Health News:SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets 2Health News:ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009 2
... Store 200 to 350 Liters of pure ... and Distribution of Purified Water,Millipores compact S.D.S. ... store 200 to 350 liters of purified ... and to maintain consistent purity of stored ...
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
Medicine Products: